Induction of lysis by T cell receptor gamma delta+/CD3+ T lymphocytes via CD2 requires triggering via the T11.1 epitope only. 1989

P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
Department of Immunology, Dr. Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.

The requirements for activation of the lytic machinery through CD2 of TCR gamma delta+/CD3+ cells were examined, by utilizing bispecific heteroconjugates containing anti-CD2 mAb cross-linked to anti-DNP. Contrary to the CD2 activation requirements in TCR alpha beta+/CD3+ cells, cytotoxic activity in TCR gamma delta+/CD3+ clones and TCR-/CD3- NK cell clones can be induced by heteroconjugates containing a single anti-CD2 (OKT11.1) mAb. Activation of TCR gamma delta+/CD3+ cells via CD2 is independent of heteroconjugates binding to CD16 (Fc gamma RIII), because heteroconjugates prepared from Fab fragments induced equal levels of lysis. Moreover, anti-CD16 mAb did not inhibit triggering via CD2 in TCR gamma delta+/CD3+ cells. In TCR-/CD3- NK cells, however, induction of cytotoxicity via CD2 is co-dependent on interplay with CD16. Anti-CD3 mAb blocked the anti-CD2 x anti-DNP heteroconjugate-induced cytotoxicity of TCR gamma delta+/CD3+ cells, indicating a functional linkage between CD2 and CD3 on these cells. We conclude that induction of lysis via CD2 shows qualitatively different activation requirements in TCR gamma delta+/CD3+, TCR alpha beta+/CD3+ CTL and TCR-/CD3- NK cells.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D011961 Receptors, Fc Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules. Fc Receptors,Fc Receptor,Receptor, Fc
D002999 Clone Cells A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) Clones,Cell, Clone,Cells, Clone,Clone,Clone Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004136 Dinitrobenzenes Benzene derivatives which are substituted with two nitro groups in the ortho, meta or para positions. Dinitrobenzene,Dinitrophenyl Compound,Dinitrophenyl Compounds,Dinitrotoluene,Dinitrotoluenes,Compound, Dinitrophenyl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D000943 Antigens, Differentiation Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation. Differentiation Antigen,Differentiation Antigens,Differentiation Antigens, Hairy Cell Leukemia,Differentiation Marker,Differentiation Markers,Leu Antigen,Leu Antigens,Marker Antigen,Marker Antigens,Markers, Differentiation,Antigen, Differentiation,Antigen, Leu,Antigen, Marker,Antigens, Leu,Antigens, Marker,Marker, Differentiation

Related Publications

P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
January 1990, International immunology,
P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
January 1990, Immunology letters,
P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
June 1986, Journal of immunology (Baltimore, Md. : 1950),
P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
May 1990, Journal of immunology (Baltimore, Md. : 1950),
P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
March 1989, Journal of immunology (Baltimore, Md. : 1950),
P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
December 1989, Nature,
P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
April 1990, Clinical and experimental immunology,
P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
August 1988, Journal of immunology (Baltimore, Md. : 1950),
P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
March 1992, Cellular immunology,
P S Goedegebuure, and D M Segal, and E Braakman, and R J Vreugdenhil, and B A Van Krimpen, and R J Van de Griend, and R L Bolhuis
January 1991, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!